Plasma cytokine profile in patients with severe COVID-19
European Journal of Human Genetics
; 31(Supplement 1):708, 2023.
Article
in English
| EMBASE | ID: covidwho-20233214
ABSTRACT
Background/Objectives:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease (COVID-19) enters the lung tissue through exocytosis, leading to the release of a large amount of pro-inflammatory cytokines called 'cytokine storm'. The aim was to provide more insight into relationship between plasma cytokines profile and fatal outcome of COVID-19. Method(s) Plasma cytokines (IL-17F,GM-CSF,IFNg,IL-10,CCL20/ MIP3a,IL-12P70,IL-13, IL-15,IL-17A,IL-22,IL-9,IL-1b,IL-33,IL-2,IL-21,IL-4,IL-23,IL-5,IL-6,IL-17E/IL-25,IL-27,IL-31,TNFa,TNFb,IL-28A) were detected in 30 patients with severe COVID-19 by a Luminex assay system with Milliplex Human Th17 Magnetic Premix 25 Plex Kit (HT17MG-14K-PX-25, Merk-Millipore, USA) according to the instructions. Patients were followed up for 30 days since admission to intensive care. 18 patients died and 12 patients survived during the period of observation. The control group comprised 10 individuals who had never been diagnosed with COVID-19. Result(s) IL-10 and CCL20/MIP3a plasma levels were elevated in non-survivors patients with COVID-19 compared to controls (p = 0.0027, p = 0.012, respectively). IL-15, IL-6, IL-27 plasma levels were higher in survivors with COVID-19 compared to controls (p = 0.049, p = 0.026, p = 0.00032, respectively). Interestingly, IL-15, IL-27 plasma levels were increased in non-survivors with COVID-19 compared to controls and survivors with severe COVID-19 (IL-15 p = 0.00098, p = 0.00014, respectively;IL-27 p = 0.011, p < 0.0001, respectively). Receiver operating characteristic (ROC) analysis has been conducted for IL-15 and IL-27. Cut-off value was estimated as 25.50 pg/ml for IL-15 and 1.51 pg/ml for IL-27. Conclusion(s) Our study demonstrated a more pronounced immune response in non-surviving patients with severe COVID-19. IL-15, IL-27 could be considered as a sensitive biomarker of the fatal outcome from COVID-19.
adult; clinical article; conference abstract; controlled study; coronavirus disease 2019; diagnosis; fatality; female; human; human tissue; immune response; intensive care; male; protein blood level; receiver operating characteristic; survivor; biological marker; cytokine; endogenous compound; granulocyte macrophage colony stimulating factor; interleukin 1; interleukin 10; interleukin 12p70; interleukin 13; interleukin 15; interleukin 17; interleukin 17F; interleukin 1beta; interleukin 2; interleukin 21; interleukin 22; interleukin 23; interleukin 25; interleukin 27; interleukin 28A; interleukin 31; interleukin 33; interleukin 4; interleukin 5; interleukin 6; interleukin 9; lymphotoxin; macrophage inflammatory protein 3alpha; tumor necrosis factor
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Language:
English
Journal:
European Journal of Human Genetics
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS